Literature DB >> 9370837

Magnesium sulphate for control of spasms in severe tetanus. Can we avoid sedation and artificial ventilation?

D Attygalle1, N Rodrigo.   

Abstract

A prospective pilot study was undertaken to investigate the ability of magnesium sulphate to control the spasms of severe tetanus without the need for sedation and artificial ventilation. All eight patients admitted with severe tetanus to our intensive care unit within the last year were given magnesium sulphate intravenously as a 5-g loading dose followed by an infusion of 2-3 gh-1. The infusion rate was increased to control spasms while retaining the patella tendon reflex, which proved a valid guide to avoid overdose. Spasms were effectively controlled and serum magnesium concentrations were maintained within the therapeutic range. Spontaneous ventilation was adequate, ventilatory support being required only for the management of lung pathology. There was no evidence of cardiovascular instability due to sympathetic over activity. No supplementary sedation was required for the control of spasms or autonomic dysfunction during magnesium therapy. We conclude that magnesium sulphate can be used as the sole agent for the control of spasms in tetanus without the need for sedation and artificial ventilation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370837     DOI: 10.1111/j.1365-2044.1997.206-az0340.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  10 in total

Review 1.  Tetanus.

Authors:  J J Farrar; L M Yen; T Cook; N Fairweather; N Binh; J Parry; C M Parry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

Review 2.  Post-neonatal tetanus: issues in intensive care management.

Authors:  S Singhi; V Jain; C Subramanian
Journal:  Indian J Pediatr       Date:  2001-03       Impact factor: 1.967

Review 3.  [Treatment strategies for tetanus].

Authors:  T Duning; W R Schäbitz
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

4.  Blindness in a case of tetanus.

Authors:  H C Hughes; D Blackburn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

5.  Managing Severe Tetanus without Ventilation Support in a Resource-limited Setting in Bangladesh.

Authors:  Md Golam Hasnain; Shomik Maruf; Proggananda Nath; Azim Anuwarul; Md Nasir Uddin Ahmed; Iqbal Hossain Chowdhury; Ariful Basher
Journal:  Am J Trop Med Hyg       Date:  2018-11       Impact factor: 2.345

6.  Tetanus.

Authors:  Sarice L. Bassin
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

7.  Prolonged high-dose intravenous magnesium therapy for severe tetanus in the intensive care unit: a case series.

Authors:  Menelaos Karanikolas; Dimitrios Velissaris; Markos Marangos; Vassilios Karamouzos; Fotini Fligou; Kriton S Filos
Journal:  J Med Case Rep       Date:  2010-03-31

Review 8.  Diazepam for treating tetanus.

Authors:  C N Okoromah; F E A Lesi
Journal:  Cochrane Database Syst Rev       Date:  2004

9.  Risk factors associated with mechanical ventilation, autonomic nervous dysfunction and physical outcome in Vietnamese adults with tetanus.

Authors:  Rachel Davies-Foote; Truong Ngoc Trung; Nguyen Van Thanh Duoc; Du Hong Duc; Phung Tran Huy Nhat; Vo Thi Nhu Trang; Nguyen Thi Kim Anh; Pham Thi Lieu; Duong Bich Thuy; Nguyen Thanh Phong; Nguyen Thanh Truong; Pham Ba Thanh; Dong Thi Hoai Tam; Tran Thi Diem Thuy; Pham Thi Tuyen; Thanh Tran Tan; James Campbell; Zudin Puthucheary; Lam Minh Yen; Nguyen Van Hao; C Louise Thwaites
Journal:  Trop Med Health       Date:  2021-06-21

10.  Comparison of sufentanil with sufentanil plus magnesium sulphate for sedation in the intensive care unit using bispectral index.

Authors:  Dilek Memiş; Alparslan Turan; Beyhan Karamanlioglu; Nihal Oguzhan; Zafer Pamukçu
Journal:  Crit Care       Date:  2003-08-28       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.